In a November 12, 2026 response to Long Covid Advocacy Ireland’s Pamela Morrison, HSE Chief Clinical Officer Dr. Colm Henry acknowledges frustration over the unavailability of non-mRNA COVID-19 vaccine Nuvaxovid and states the HSE is continuing efforts to secure stock for the winter 2026/2027 programme. He notes that while NIAC preferentially recommends mRNA vaccines for at-risk groups, Nuvaxovid is recommended for those with contraindications or who choose not to take mRNA vaccines, yet is currently unavailable in Ireland and across much of Europe due to supply barriers outside the HSE’s control, prompting outreach inside and outside Europe as well as with the manufacturer. Dr. Henry adds that 173 doses were administered as early as possible after arriving last winter, outlines how patients can join the HSELive callback list (1800 700 700), and states that guidance and supply updates are shared with GPs, pharmacists, and other clinicians via training materials, webinars, and FAQs while Nuvaxovid in the community is delivered through HSE vaccination teams
